News

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative ...
Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...
Co-founder and CEO Jareeporn Jarukornsakul built industrial parks developer WHA from the ground up. Now she's facing the ...
GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the promising field of liver therapies.
We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE: GSK) stands against other ...
GSK already has six manufacturing sites in the US, including an $800mn investment under construction in Pennsylvania that was announced last year.
After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are planning a move northeast to Cambridge, Massachusetts, the company confirmed ...
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-bas ...
Following outlays for sites in the UK and Belgium earlier this year, GSK is planning to invest up to $800m in the US to double the size and capacity of its site in Marietta, Pennsylvania.